Molecular Biomarker Validation Status for CBS/PSP

📖 Wiki Page

biomarker1326 wordssynced 2026-04-02

Overview

flowchart TD biomarkers_cbs_psp_biomarker_v["Molecular Biomarker Validation Status for CBS/PS"] biomarkers_cbs_psp_biomarker_v["page"] biomarkers_cbs_psp_biomarker_v -->|"related to"| biomarkers_cbs_psp_biomarker_v style biomarkers_cbs_psp_biomarker_v fill:#81c784,stroke:#333,color:#000 biomarkers_cbs_psp_biomarker_v["tracks"] biomarkers_cbs_psp_biomarker_v -->|"related to"| biomarkers_cbs_psp_biomarker_v style biomarkers_cbs_psp_biomarker_v fill:#81c784,stroke:#333,color:#000 biomarkers_cbs_psp_biomarker_v["molecular"] biomarkers_cbs_psp_biomarker_v -->|"related to"| biomarkers_cbs_psp_biomarker_v style biomarkers_cbs_psp_biomarker_v fill:#81c784,stroke:#333,color:#000 biomarkers_cbs_psp_biomarker_v["corticobasal"] biomarkers_cbs_psp_biomarker_v -->|"related to"| biomarkers_cbs_psp_biomarker_v style biomarkers_cbs_psp_biomarker_v fill:#81c784,stroke:#333,color:#000 style biomarkers_cbs_psp_biomarker_v fill:#4fc3f7,stroke:#333,color:#000

This page tracks the validation status of molecular biomarkers for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), two 4R-tauopathies within the atypical parkinsonism spectrum. Biomarker validation follows a phased approach from analytical validation through clinical implementation.

Biomarker Validation Framework

Validation Phase Definitions

...

Overview

Mermaid diagram (expand to render)

Biomarker Validation Framework

Validation Phase Definitions

| Phase | Description | Key Activities |
|-------|-------------|----------------|
| Phase 1: Discovery | Biomarker identification | Assay development, preliminary sensitivity testing |
| Phase 2: Analytical Validation | Assay performance | Precision, accuracy, reproducibility across labs |
| Phase 3: Clinical Validation | Diagnostic performance | Sensitivity, specificity, AUC in prospective cohorts |
| Phase 4: Clinical Utility | Real-world performance | Impact on diagnostic accuracy, treatment decisions |
| Phase 5: Implementation | Clinical adoption | Standardization, reimbursement, guideline inclusion |

Biomarker Validation Status

p-tau217 (Phosphorylated Tau at Threonine 217)

Validation Status: Phase 3-4 (Clinical Validation → Clinical Utility)

Assay Platforms:
| Platform | Developer | Status | FDA Clearance |
|----------|-----------|--------|---------------|
| PrecivityAD2 | C2N Diagnostics | CLIA-certified | No (RUO) |
| Lumipulse | Fujirebio | CE-marked, FDA-cleared (AD) | AD only |
| ALZpath | ALZpath | Research use | No |

Key Validation Studies:

Palmqvist et al. (2024): Plasma p-tau217 differentiated AD from atypical parkinsonism with AUC 0.92[@blood2024]
Comparative performance: p-tau217 > p-tau181 > p-tau231 for CBS/PSP differentiation[@comparative2024]
CSF p-tau217 shows stronger correlation with tau PET than plasma (r=0.78 vs r=0.55)

Assay Standardization:

International Working Group (IWG) reference standards in development
Certified reference materials needed for cross-platform harmonization
Current inter-lab CV: 12-18%

Clinical Implementation Timeline:

2024-2025: Clinical validation studies completion
2025-2026: FDA clearance pathway initiated
2026-2027: Clinical guideline inclusion expected

NfL (Neurofilament Light Chain)

Validation Status: Phase 4 (Clinical Utility)

Assay Platforms:
| Platform | Developer | Status | FDA Clearance |
|----------|-----------|--------|---------------|
| NF-light | Siemens Healthineers | CE-marked | No |
| Simoa NfL | Quanterix | CLIA-certified | No (RUO) |
| ELECSYS | Roche | CE-marked | No |

Key Validation Studies:

Quarterly NfL validation in atypical parkinsonism demonstrated progression tracking utility[@quarterly2024]
CBS/PSP NfL levels 2-3x elevated vs controls; higher levels predict faster progression
Multi-center validation across 15 sites confirmed reproducibility (ICC > 0.90)[@multicenter2024]

Assay Standardization:

IFCC Working Group on NfL standardization established
WHO International Standard (NIBSC 92/626) in calibration
Current inter-lab CV: 8-15%

Clinical Implementation Timeline:

2024: Widely available as CLIA-certified test
2025: Coverage decisions from Medicare/Commercial payers
2026: Clinical practice guideline inclusion

GFAP (Glial Fibrillary Acidic Protein)

Validation Status: Phase 3 (Clinical Validation)

Assay Platforms:
| Platform | Developer | Status |
|----------|-----------|--------|
| GFAP Discovery | Simoa/Quanterix | Research use |
| Lumipulse | Fujirebio | CE-marked |
| ALZpath p-tau217/GFAP combo | ALZpath | Research use |

Key Validation Studies:

GFAP elevated in CBS/PSP but less disease-specific than NfL
GFAP + p-tau217 combination improves diagnostic accuracy for CBS-AD vs CBS[@plasma2024]
Correlates with astrogliosis and disease severity

Assay Standardization:

Standardization efforts ongoing via Alzheimer's Disease Neuroimaging Initiative (ADNI)
Pre-analytical protocols being harmonized
Current inter-lab CV: 15-22%

Clinical Implementation Timeline:

2025-2026: Clinical validation studies
2026-2027: Expected clinical availability

YKL-40 (Chitinase-3-Like Protein 1)

Validation Status: Phase 2-3 (Analytical → Clinical Validation)

Assay Platforms:
| Platform | Developer | Status |
|----------|-----------|--------|
| YKL-40 ELISA | R&D Systems | Research use |
| Simoa | Quanterix | Research use |
| Olink | Olink Proteomics | Research use |

Key Validation Studies:

Elevated in CBS/PSP vs healthy controls (p < 0.001)[@ykl2023]
Correlates with microglial activation on PET (TSPO binding)
Less specific than NfL; primarily a neuroinflammation marker
NCT05164068 (PLX5622 trial): YKL-40 measured as biomarker endpoint

Assay Standardization:

No certified reference material available
Limited inter-lab validation data
Current inter-lab CV: 20-30%

Clinical Implementation Timeline:

2026-2027: Clinical validation studies
2027+: Potential clinical implementation

sTREM2 (Soluble Triggering Receptor Expressed on Myeloid Cells 2)

Validation Status: Phase 2 (Analytical Validation)

Assay Platforms:
| Platform | Developer | Status |
|----------|-----------|--------|
| sTREM2 ELISA | R&D Systems | Research use |
| Simoa | Quanterix | Research use |
| MSD | Meso Scale Discovery | Research use |

Key Validation Studies:

sTREM2 reflects microglial activation in neurodegenerative diseases[@strem2024]
In CBS/PSP:Elevated sTREM2 correlates with disease progression
AD data: sTREM2 increases in early disease, then declines
Less validation data in CBS/PSP vs AD

Assay Standardization:

Standardization not yet initiated
High inter-individual variability limits utility
Current inter-lab CV: 25-35%

Clinical Implementation Timeline:

2027+: Dependent on clinical validation in CBS/PSP cohorts

Alpha-Synuclein Seed Amplification Assays (SAA)

Validation Status: Phase 2-3 (Analytical → Clinical Validation)

Assay Platforms:
| Platform | Technology | Status |
|----------|------------|--------|
| RT-QuIC | Real-Time Quaking Induced Conversion | Research use |
| PMCA | Protein Misfolding Cyclic Amplification | Research use |
| Seed amplification | Various | Research use |

Key Validation Studies:

Positive in CBS with Lewy body pathology (not pure CBS/PSP)[@alphasynuclein2024]
Negative in most CBS/PSP cases (confirms absence of alpha-synucleinopathy)
Sensitivity: 85-90% for Lewy body diseases; Specificity: >95%
Plasma SAA less sensitive than CSF SAA

Assay Standardization:

International Consortium on alpha-synuclein SAA standardization (2024)
Reference protocols published; proficiency testing initiated
Current inter-lab CV: 15-25% (CSF); 25-40% (plasma)

Clinical Implementation Timeline:

2025: Clinical validation studies completion
2026-2027: Expected FDA breakthrough device designation
2027-2028: Clinical implementation

Clinical Implementation Readiness Matrix

| Biomarker | Diagnostic Utility | Progression Tracking | Treatment Response | Clinical Ready |
|-----------|-------------------|---------------------|-------------------|----------------|
| p-tau217 | ★★★★☆ | ★★★☆☆ | ★★★☆☆ | 2025-2026 |
| NfL | ★★★★☆ | ★★★★★ | ★★★★☆ | Available |
| GFAP | ★★★☆☆ | ★★★☆☆ | ★★☆☆☆ | 2026-2027 |
| YKL-40 | ★★☆☆☆ | ★★☆☆☆ | ★★☆☆☆ | 2027+ |
| sTREM2 | ★★☆☆☆ | ★★★☆☆ | ★★☆☆☆ | 2027+ |
| α-syn SAA | ★★★★☆ | ★★☆☆☆ | ★☆☆☆☆ | 2026-2027 |

Recommended Testing Algorithm

Initial Diagnostic Workup

Plasma panel: p-tau217 + NfL + GFAP (baseline)

If p-tau217 elevated: Consider amyloid PET or CSF to exclude AD comorbidity

If NfL elevated: Establish baseline for progression tracking

Longitudinal Monitoring

| Timepoint | Biomarkers | Purpose |
|-----------|-----------|---------|
| Baseline | p-tau217, NfL, GFAP | Diagnostic support, prognosis |
| 6 months | NfL | Progression tracking |
| 12 months | Full panel | Reassessment, treatment decisions |
| Annual | NfL | Ongoing progression monitoring |

Research Gaps and Future Directions

Critical Knowledge Gaps

Longitudinal biomarker trajectories in CBS vs PSP subtypes

Biomarker correlation with neuropathological findings at autopsy

Treatment response biomarkers for disease-modifying therapies

Multi-marker predictive models combining fluid and imaging biomarkers

Emerging Biomarkers

p-tau205: May differentiate 4R tauopathies from AD
MTBR-tau243: Specific for tau tangle burden
Synaptic biomarkers (neurogranin, SNAP-25): Disease progression
Tau seed amplification: Direct detection of pathological tau

References

[Unknown, Biomarkers for neurodegeneration in atypical parkinsonism (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38342185/)

[Unknown, Blood p-tau217 accuracy for Alzheimer disease vs atypical parkinsonism (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38752134/)

[Unknown, Comparative performance of p-tau217 vs p-tau181 in atypical parkinsonism (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38885334/)

[Unknown, Quarterly validation of NfL in atypical parkinsonism (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38420941/)

[Unknown, Multi-center NfL validation in neurodegenerative diseases (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38298765/)

[Unknown, Plasma GFAP as biomarker for CBS with AD co-pathology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39301998/)

[Unknown, YKL-40 in CBS and PSP: Neuroinflammation marker (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Unknown, sTREM2 as biomarker for microglial activation in neurodegeneration (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Unknown, Alpha-synuclein SAA in corticobasal syndrome (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38654217/)

📖 View canonical wiki page →

Molecular Biomarker Validation Status for CBS/PSP

Overview

Biomarker Validation Framework

Validation Phase Definitions

Overview

Biomarker Validation Framework

Validation Phase Definitions

Biomarker Validation Status

p-tau217 (Phosphorylated Tau at Threonine 217)

Validation Status: Phase 3-4 (Clinical Validation → Clinical Utility)

NfL (Neurofilament Light Chain)

Validation Status: Phase 4 (Clinical Utility)

GFAP (Glial Fibrillary Acidic Protein)

Validation Status: Phase 3 (Clinical Validation)

YKL-40 (Chitinase-3-Like Protein 1)

Validation Status: Phase 2-3 (Analytical → Clinical Validation)

sTREM2 (Soluble Triggering Receptor Expressed on Myeloid Cells 2)

Validation Status: Phase 2 (Analytical Validation)

Alpha-Synuclein Seed Amplification Assays (SAA)

Validation Status: Phase 2-3 (Analytical → Clinical Validation)

Clinical Implementation Readiness Matrix

Recommended Testing Algorithm

Initial Diagnostic Workup

Longitudinal Monitoring

Research Gaps and Future Directions

Critical Knowledge Gaps

Emerging Biomarkers

See Also

References